Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry's PMS activities branded "unsatisfactory"

This article was originally published in RAJ Devices

Executive Summary

Postmarket surveillance activities by medical device manufacturers in the UK remain unsatisfactory and some companies still view their clinical trial data as private property, despite this being unethical and against trade association guidance. These were some of the key points to emerge from a meeting of medtech experts hosted by the UK Medicines and Healthcare products Regulatory Agency.

You may also be interested in...



COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data

The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.

India Permits Sale Of Some Devices Beyond Licensing Deadline

Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.

Australia Considers Redefining Central Circulatory System To Align With EU

Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions. 

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel